Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegpleranib and Ranibizumab for Severe Ocular Von Hippel-Lindau Disease
NCT02859441Phase 2Completed
- Sponsor
- National Eye Institute
- Start
- Jan 2017
- Primary completion
- Jul 2019
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
A Phase 2 trial of pegpleranib in von Hippel–Lindau disease (VHL), sponsored by National Eye Institute. Started Jan 2017; status: completed.
02
Drugs
pegpleranib
03
Conditions
von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT02859441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859441.